Arcus Biosciences, Inc.
NYSE:RCUSBiotechnology
-$0.09 today
- Market cap
- $2.27B
- Beta
- 0.84
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$2.94
Volume 1.97M
Average 1.17M
RCUS EBITDA Margin
EBITDA as a percentage of revenue.
Arcus Biosciences, Inc.NYSE: RCUS
EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026
EBITDA Margin narrows to -207.3%
EBITDA Margin was -207.3% in Q2 FY2026, down 209.8 pp from a year earlier. On a trailing-twelve-month basis it was -358.1%, down 250.5 pp year over year. Over 3 fiscal years it widened by 94.7 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 10 analysts of -507.9% for the fiscal year ending Dec 2026, down from -135.6% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -207.3%+516.2 pp QoQ
- Last fiscal yearDec 2025
- -135.6%-31.4 pp YoY
- LTMJun 2026
- -358.1%-250.5 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -135.6%
- Year-over-year change
- -31.4pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -135.6% | -31.4pp |
| FY2024 | 2024-12-31 | -104.3% | +144.5pp |
| FY2023 | 2023-12-31 | -248.7% | -18.4pp |
| FY2022 | 2022-12-31 | -230.4% | -245.8pp |
| FY2021 | 2021-12-31 | 15.4% | — |
EBITDA Margin vs competitors
How RCUS compares with its peers on the latest reported figures
- RCUS's LTM Jun 2026 EBITDA Margin of -358.1% is the 3rd highest of the 8 companies compared; the peer median is -527.0%.
- Its year-over-year change of -250.5 pp is the 5th highest of 7, against a peer median of +176.5 pp.
- Over three fiscal years its change of +94.7 pp compares with a peer median of +623.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Jun 2026 | 39.4% | +670.4 pp | +192.5 pp | |
| LTM Jun 2026 | -40.5% | +584.3 pp | +435.7 pp | |
| LTM Jun 2026 | -358.1% | -250.5 pp | +94.7 pp | |
| LTM Jun 2026 | -516.8% | +111160.6 pp | +6811.5 pp | |
| LTM Mar 2026 | -527.0% | -231.3 pp | -361.8 pp | |
| LTM Sep 2026 | -550.8% | -269.0 pp | +146419.7 pp | |
| LTM Mar 2026 | -633.4% | -2566.2 pp | +811.4 pp | |
| LTM Jun 2026 | -13823.7% | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding RCUS) | -527.0% | +176.5 pp | +623.5 pp | |
Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 383M | 112M | 117M | 258M | 247M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 10M |
| Gross Profit | 383M | 112M | 117M | 258M | 237M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 96.0% |
| Research & Development | 257M | 288M | 340M | 448M | 523M |
| Selling, General & Admin | 72M | 104M | 117M | 120M | 110M |
| Operating Expenses | 329M | 392M | 457M | 588M | 623M |
| Depreciation & Amortization | 4M | 6M | 8M | 10M | 10M |
| EBITDA | 59M | (258M) | (291M) | (269M) | (335M) |
| EBITDA Margin | 15.4% | -230.4% | -248.7% | -104.3% | -135.6% |
| Operating Income | 54M | (280M) | (340M) | (330M) | (386M) |
| Operating Margin | 14.1% | -250.0% | -290.6% | -127.9% | -156.3% |
| Interest Income | 1M | 16M | 41M | 52M | 41M |
| Interest Expense | 0 | 2M | 2M | 4M | 8M |
| Other Income / Expenses | 1M | 14M | 39M | 47M | 33M |
| Income Before Tax | 55M | (266M) | (301M) | (283M) | (353M) |
| Pre-Tax Margin | 14.4% | -237.5% | -257.3% | -109.7% | -142.9% |
| Income Tax Expense | 2M | 1M | 6M | 1M | 0 |
| Net Income | 53M | (267M) | (307M) | (283M) | (353M) |
| Net Margin | 13.8% | -238.4% | -262.4% | -109.7% | -142.9% |
| EPS (Basic) | 0.76 | (3.71) | (4.15) | (3.14) | (3.29) |
| EPS (Diluted) | 0.71 | (3.71) | (4.15) | (3.14) | (3.29) |
| Weighted Avg Shares | 69.35M | 72M | 74M | 90.1M | 107.4M |
| Weighted Avg Shares (Diluted) | 73.97M | 72M | 74M | 90.1M | 107.4M |
Arcus Biosciences, Inc.
NYSE:RCUS
Intrinsic Alpha fair value
Locked
Current Price
$15.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.